WINTON GROUP Ltd Has $1.22 Million Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

WINTON GROUP Ltd decreased its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 10.3% during the 4th quarter, HoldingsChannel.com reports. The firm owned 40,436 shares of the biopharmaceutical company’s stock after selling 4,645 shares during the quarter. WINTON GROUP Ltd’s holdings in TG Therapeutics were worth $1,217,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in TGTX. Arizona State Retirement System increased its stake in TG Therapeutics by 0.9% in the fourth quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company’s stock valued at $1,283,000 after acquiring an additional 364 shares during the period. Blue Trust Inc. grew its position in TG Therapeutics by 24.5% during the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock worth $57,000 after acquiring an additional 371 shares during the last quarter. Brookstone Capital Management raised its holdings in TG Therapeutics by 3.7% during the 4th quarter. Brookstone Capital Management now owns 17,521 shares of the biopharmaceutical company’s stock worth $527,000 after purchasing an additional 624 shares during the last quarter. Daymark Wealth Partners LLC lifted its position in TG Therapeutics by 1.7% during the 4th quarter. Daymark Wealth Partners LLC now owns 41,500 shares of the biopharmaceutical company’s stock valued at $1,249,000 after purchasing an additional 689 shares during the period. Finally, New York State Teachers Retirement System grew its position in shares of TG Therapeutics by 1.9% during the 4th quarter. New York State Teachers Retirement System now owns 43,764 shares of the biopharmaceutical company’s stock worth $1,317,000 after buying an additional 837 shares during the period. 58.58% of the stock is currently owned by institutional investors.

TG Therapeutics Trading Down 1.4 %

NASDAQ:TGTX opened at $40.20 on Friday. The stock has a market capitalization of $6.31 billion, a PE ratio of -401.96 and a beta of 2.30. TG Therapeutics, Inc. has a fifty-two week low of $12.93 and a fifty-two week high of $43.32. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The business’s 50-day simple moving average is $34.17 and its 200-day simple moving average is $30.18.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.08 by $0.07. The business had revenue of $108.19 million during the quarter, compared to the consensus estimate of $100.67 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. Sell-side analysts expect that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. StockNews.com raised TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and set a $55.00 price objective on shares of TG Therapeutics in a research note on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $40.67.

Insiders Place Their Bets

In related news, CFO Sean A. Power sold 10,021 shares of the firm’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $28.53, for a total value of $285,899.13. Following the completion of the transaction, the chief financial officer now directly owns 660,611 shares of the company’s stock, valued at approximately $18,847,231.83. This trade represents a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 10.50% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.